Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RUXOLITINIB Cause Dermatitis exfoliative generalised? 19 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Dermatitis exfoliative generalised have been filed in association with RUXOLITINIB (OPZELURA). This represents 0.0% of all adverse event reports for RUXOLITINIB.

19
Reports of Dermatitis exfoliative generalised with RUXOLITINIB
0.0%
of all RUXOLITINIB reports
2
Deaths
13
Hospitalizations

How Dangerous Is Dermatitis exfoliative generalised From RUXOLITINIB?

Of the 19 reports, 2 (10.5%) resulted in death, 13 (68.4%) required hospitalization.

Is Dermatitis exfoliative generalised Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for RUXOLITINIB. However, 19 reports have been filed with the FAERS database.

What Other Side Effects Does RUXOLITINIB Cause?

Off label use (12,492) Death (6,561) Fatigue (5,663) Anaemia (3,593) Haemoglobin decreased (3,297) Platelet count decreased (3,028) Diarrhoea (2,531) Asthenia (2,529) Dizziness (2,398) Pneumonia (2,343)

What Other Drugs Cause Dermatitis exfoliative generalised?

ALLOPURINOL (192) DUPILUMAB (162) METHOTREXATE (151) SULFAMETHOXAZOLE\TRIMETHOPRIM (140) AMOXICILLIN (122) ADALIMUMAB (113) PANTOPRAZOLE (105) SECUKINUMAB (96) VANCOMYCIN (92) AMLODIPINE (91)

Which RUXOLITINIB Alternatives Have Lower Dermatitis exfoliative generalised Risk?

RUXOLITINIB vs SABRIL RUXOLITINIB vs SACCHAROMYCES CEREVISIAE RUXOLITINIB vs SACITUZUMAB GOVITECAN RUXOLITINIB vs SACITUZUMAB GOVITECAN-HZIY RUXOLITINIB vs SACROSIDASE

Related Pages

RUXOLITINIB Full Profile All Dermatitis exfoliative generalised Reports All Drugs Causing Dermatitis exfoliative generalised RUXOLITINIB Demographics